- User Profile
- Watchlists
- Healthcare & Biotech (17)
Healthcare & Biotech (17)
Thematic Narrative Collections #4 - Healthcare & Biotech
Drug developers, medtech and the science behind the next treatments. One handpicked community Narrative per stock, chosen by the Simply Wall St team, so you can track the whole theme in one place. Updated regularly.
Narratives are community opinions, not recommendations or financial advice. Do your own research.
Watching
17
FV & Narrative | Valuation | Growth | Analyst Target | |||
|---|---|---|---|---|---|---|
CUE Cue Biopharma US$37.0547.1% undervalued intrinsic discount 28.9%7D 30.2%3M | ||||||
CNXU Conexeu Sciences US$4.9680.4% undervalued intrinsic discount 11.2%7D -62.7%3M | ||||||
ARCT Arcturus Therapeutics Holdings US$16.0346.6% undervalued intrinsic discount 8.8%7D 112.9%3M | ||||||
MBIO Mustang Bio US$0.5470.0% undervalued intrinsic discount 6.4%7D -17.0%3M | ||||||
CSL CSL AU$175.5916.4% undervalued intrinsic discount 5.1%7D 51.0%3M | ||||||
HYFT MindWalk Holdings US$1.3627.7% undervalued intrinsic discount 4.2%7D -11.1%3M | ||||||
LLY Eli Lilly US$1,152.9321.9% undervalued intrinsic discount 3.3%7D 4.9%3M | ||||||
PME Pro Medicus AU$169.5713.8% undervalued intrinsic discount 3.2%7D -1.9%3M | ||||||
BANB Bachem Holding CHF 78.5568.6% undervalued intrinsic discount 2.1%7D 15.6%3M | ||||||
NOVO B Novo Nordisk DKK 281.5566.9% undervalued intrinsic discount 1.8%7D -3.9%3M | ||||||
HIMS Hims & Hers Health US$27.9983.6% undervalued intrinsic discount 1.7%7D -21.1%3M | ||||||
GANX Gain Therapeutics US$1.7676.8% undervalued intrinsic discount 0.6%7D -6.4%3M | ||||||
VEEV Veeva Systems US$260.2132.1% undervalued intrinsic discount -0.8%7D 69.7%3M | ||||||
CBAV Clínica Baviera €56.4037.8% undervalued intrinsic discount -1.1%7D 0.7%3M | ||||||
CRMD CorMedix US$7.7240.6% undervalued intrinsic discount -1.3%7D -11.0%3M | ||||||
ZTS Zoetis US$71.4021.8% undervalued intrinsic discount -2.2%7D -9.3%3M | ||||||
UNCY Unicycive Therapeutics US$4.8077.7% undervalued intrinsic discount -9.3%7D -29.9%3M |
Watching
17
FV & Narrative | Valuation | Growth | Analyst Target | |||
|---|---|---|---|---|---|---|
CUE Cue Biopharma 28.9%7D 30.2%3M | US$37.05 47.1% undervalued intrinsic discount | PS 7.1x | E -3.3% | US$90.50 | ||
CNXU Conexeu Sciences 11.2%7D -62.7%3M | US$4.96 80.4% undervalued intrinsic discount | PB 19.4x | E 64.6% | US$20.00 | ||
ARCT Arcturus Therapeutics Holdings 8.8%7D 112.9%3M | US$16.03 46.6% undervalued intrinsic discount | PS 15.5x | E 28.0% | US$22.30 | ||
MBIO Mustang Bio 6.4%7D -17.0%3M | US$0.54 70.0% undervalued intrinsic discount | PB 0.5x | S n/a | n/a | ||
CSL CSL 5.1%7D 51.0%3M | AU$175.59 16.4% undervalued intrinsic discount | PS 3.8x | E 44.5% | AU$177.23 | ||
HYFT MindWalk Holdings 4.2%7D -11.1%3M | US$1.36 27.7% undervalued intrinsic discount | PS 5.5x | E 38.5% | US$4.33 | ||
LLY Eli Lilly 3.3%7D 4.9%3M | US$1,152.93 21.9% undervalued intrinsic discount | PE 38.5x | E 17.0% | US$1,325.39 | ||
PME Pro Medicus 3.2%7D -1.9%3M | AU$169.57 13.8% undervalued intrinsic discount | PE 66.8x | E 5.8% | AU$202.47 | ||
BANB Bachem Holding 2.1%7D 15.6%3M | CHF 78.55 68.6% undervalued intrinsic discount | PE 39.5x | E 17.7% | CHF 84.30 | ||
NOVO B Novo Nordisk 1.8%7D -3.9%3M | DKK 281.55 66.9% undervalued intrinsic discount | PE 10.7x | E 1.2% | DKK 310.17 | ||
HIMS Hims & Hers Health 1.7%7D -21.1%3M | US$27.99 83.6% undervalued intrinsic discount | PS 2.5x | E 65.1% | US$31.29 | ||
GANX Gain Therapeutics 0.6%7D -6.4%3M | US$1.76 76.8% undervalued intrinsic discount | PB 6.8x | E 37.7% | US$7.20 | ||
VEEV Veeva Systems -0.8%7D 69.7%3M | US$260.21 32.1% undervalued intrinsic discount | PE 41.5x | E 12.6% | US$297.30 | ||
CBAV Clínica Baviera -1.1%7D 0.7%3M | €56.40 37.8% undervalued intrinsic discount | PE 19.7x | S n/a | n/a | ||
CRMD CorMedix -1.3%7D -11.0%3M | US$7.72 40.6% undervalued intrinsic discount | PE 3.2x | E -3.2% | US$15.40 | ||
ZTS Zoetis -2.2%7D -9.3%3M | US$71.40 21.8% undervalued intrinsic discount | PE 11.2x | E 3.5% | US$96.00 | ||
UNCY Unicycive Therapeutics -9.3%7D -29.9%3M | US$4.80 77.7% undervalued intrinsic discount | PB 2.5x | E 48.5% | US$29.60 |